REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Files An 8-K Financial Statements and ExhibitsITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
|
Number |
Description |
|
99.1 |
Press Release entitled “Revance Therapeutics Expands Leadership Team, Appointing Todd Zavodnick Chief Commercial Officer and President, Aesthetics & Therapeutics” |
Revance Therapeutics, Inc. ExhibitEX-99.1 2 rvnc8-2x17exhibit991.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 Revance Therapeutics Expands Leadership Team,…To view the full exhibit click here
About REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC)
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.
